[go: up one dir, main page]

HN2001000013A - PIRIDO [2,3 - d] PIRIMIDIN - 2, 7 - DIAMINAS INHIBIDORES DE CINASAS - Google Patents

PIRIDO [2,3 - d] PIRIMIDIN - 2, 7 - DIAMINAS INHIBIDORES DE CINASAS

Info

Publication number
HN2001000013A
HN2001000013A HN2001000013A HN2001000013A HN2001000013A HN 2001000013 A HN2001000013 A HN 2001000013A HN 2001000013 A HN2001000013 A HN 2001000013A HN 2001000013 A HN2001000013 A HN 2001000013A HN 2001000013 A HN2001000013 A HN 2001000013A
Authority
HN
Honduras
Prior art keywords
pirido
pirimidin
diamines
kinase inhibiting
enzymes
Prior art date
Application number
HN2001000013A
Other languages
English (en)
Spanish (es)
Inventor
Booth Richard John
Dobrusin Ellen Myra
Josyula Vara Prasad Venkata Nagendra
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HN2001000013A publication Critical patent/HN2001000013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
HN2001000013A 2000-01-25 2001-01-24 PIRIDO [2,3 - d] PIRIMIDIN - 2, 7 - DIAMINAS INHIBIDORES DE CINASAS HN2001000013A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
HN2001000013A true HN2001000013A (es) 2001-06-18

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2001000013A HN2001000013A (es) 2000-01-25 2001-01-24 PIRIDO [2,3 - d] PIRIMIDIN - 2, 7 - DIAMINAS INHIBIDORES DE CINASAS

Country Status (34)

Country Link
EP (1) EP1254137A1 (xx)
JP (1) JP4047010B2 (xx)
KR (1) KR20020065939A (xx)
CN (1) CN1395578A (xx)
AP (1) AP2002002586A0 (xx)
AR (1) AR030044A1 (xx)
AU (1) AU2542501A (xx)
BG (1) BG106850A (xx)
BR (1) BR0107751A (xx)
CA (1) CA2397961C (xx)
CO (1) CO5261549A1 (xx)
CR (1) CR6706A (xx)
CZ (1) CZ20022475A3 (xx)
DZ (1) DZ3266A1 (xx)
EA (1) EA200200643A1 (xx)
EE (1) EE200200405A (xx)
GT (1) GT200100016A (xx)
HN (1) HN2001000013A (xx)
HU (1) HUP0204141A3 (xx)
IL (1) IL150545A0 (xx)
IS (1) IS6443A (xx)
MA (1) MA26868A1 (xx)
MX (1) MXPA02007221A (xx)
NO (1) NO20023527L (xx)
OA (1) OA12161A (xx)
PA (1) PA8510701A1 (xx)
PE (1) PE20011066A1 (xx)
PL (1) PL356802A1 (xx)
SK (1) SK10632002A3 (xx)
SV (1) SV2002000294A (xx)
TN (1) TNSN01014A1 (xx)
WO (1) WO2001055147A1 (xx)
YU (1) YU50402A (xx)
ZA (1) ZA200205879B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
HRP20050601A2 (en) * 2002-11-28 2005-10-31 Schering Ag Chk-, pdk-, and akt-inhibitory pyrimidines, their production and use as pharmarmaceutical agents
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
EP1794160A1 (en) * 2004-09-21 2007-06-13 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd NOVEL CONNECTIONS
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
CN101243081A (zh) * 2005-07-21 2008-08-13 霍夫曼-拉罗奇有限公司 作为PTP1B抑制剂的吡啶并[2,3-d]嘧啶-2,4-二胺化合物
ATE482958T1 (de) 2005-08-09 2010-10-15 Irm Llc Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2352732B1 (en) * 2008-12-01 2013-02-20 Merck Patent GmbH 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
US9815847B2 (en) 2013-03-14 2017-11-14 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
ES2146782T3 (es) * 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
DE69939168D1 (de) * 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung

Also Published As

Publication number Publication date
PE20011066A1 (es) 2001-10-22
WO2001055147A1 (en) 2001-08-02
CN1395578A (zh) 2003-02-05
EP1254137A1 (en) 2002-11-06
HUP0204141A2 (hu) 2003-04-28
TNSN01014A1 (fr) 2005-11-10
SV2002000294A (es) 2002-07-16
MXPA02007221A (es) 2002-11-29
EA200200643A1 (ru) 2002-12-26
JP4047010B2 (ja) 2008-02-13
CO5261549A1 (es) 2003-03-31
CR6706A (es) 2005-04-04
AR030044A1 (es) 2003-08-13
IS6443A (is) 2002-06-25
KR20020065939A (ko) 2002-08-14
DZ3266A1 (fr) 2001-08-02
NO20023527D0 (no) 2002-07-24
NO20023527L (no) 2002-09-10
PA8510701A1 (es) 2002-12-11
AP2002002586A0 (en) 2002-09-30
HUP0204141A3 (en) 2005-03-29
AU2542501A (en) 2001-08-07
BR0107751A (pt) 2002-11-12
CZ20022475A3 (cs) 2003-03-12
GT200100016A (es) 2001-10-19
EE200200405A (et) 2003-12-15
JP2003523357A (ja) 2003-08-05
PL356802A1 (en) 2004-07-12
MA26868A1 (fr) 2004-12-20
CA2397961A1 (en) 2001-08-02
YU50402A (sh) 2005-11-28
CA2397961C (en) 2008-08-26
IL150545A0 (en) 2003-02-12
OA12161A (en) 2006-05-08
BG106850A (bg) 2003-02-28
ZA200205879B (en) 2003-09-29
SK10632002A3 (sk) 2003-06-03

Similar Documents

Publication Publication Date Title
HN2001000013A (es) PIRIDO [2,3 - d] PIRIMIDIN - 2, 7 - DIAMINAS INHIBIDORES DE CINASAS
USD538050S1 (en) Substrate with camouflage pattern
EP1675552A4 (en) PREPARATION OF 1,6-DISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
IS7319A (is) Fjölgervingar klópídógrelvetnissúlfats
CR6736A (es) 5-alquilpirido[2,3-d[ piridinas como inhibidores de tirosina kinasa
WO2004044158A3 (en) Human embryonic stem cell cultures, and compositions and methods for growing same
BR0010616A (pt) Sequências de ácido nucléico a proteìnas envolvidas em sìntese de isoprenóide
BG106035A (en) Heterocyclically substituted benzimidazoles, the production and utilization thereof
BR0011197A (pt) Método de tratamento de uma doença autoimunológica em um mamìfero, compreendendo antagonistas que se ligam aos marcadores de superfìcie de células b e artigo de manufatura
ECSP014105A (es) COMPUESTOS DE PIRROLO [2,3-d] PIRIMIDINA
BR0308339A (pt) Indazóis substituìdos com uma atividade anticancerosa
AP1758A (en) Method for the preparation of hexahydro-furo [2,3-b]furan-3-ol.
BRPI0414598A (pt) indóis substituìdos
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
HN1997000098A (es) Ccompuesto de indol 2, 3 sustituido como agentes antiinflamatorios y analgesicos.
BRPI0407282A (pt) Processo para preparação de inibidores de pirrolotriazina cinase
AU5354301A (en) Nucleic acid sequences to proteins involved in tocopherol synthesis
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
IL162343A0 (en) Cell constructs cultured in vitro, preparation anduses
USD490248S1 (en) Tissue with embossed puppy design
PT1153015E (pt) Pirimidina-2,4,6-trionas uteis como inibidores de metaloproteinases matriciais
WO2002038106A3 (en) Calcilytic compounds
BR0115119A (pt) Derivados tricìclicos de indol com atividade antiangiogênica
AR023979A1 (es) Procesos para preparar compuestos intermedios de plaguicidas
HN1999000116A (es) Isoquinolinas